Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded,prospective study

Journal of Psychiatric Research

Volumn 66-67, Issue , 2015, Pages 84-94

  Han, Changsu ^a   Wang, Sheng Min ^b   Kwak, Kyung Phil ^c   Won, Wang Yeon ^b   Lee, HwaYoung ^d   Chang, Chia Ming ^e   Tang, Tze Chun ^f   Pae, Chi Un ^b,g  

^a Korea University College of Medicine   (South Korea)

^b The Catholic University of Korea College of Medicine   (South Korea)

^c Dongguk University College of Medicine   (South Korea)

^d Soonchunhyang University   (South Korea)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antidepressant; Aripiprazole; Augmentation; Major depressive disorder; Switching

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; MILNACIPRAN; MIRTAZAPINE; PAROXETINE; SERTRALINE; TIANEPTINE; VENLAFAXINE;

ADULT; ARTICLE; BARNES AKATHISIA SCALE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMPLOYMENT STATUS; FATIGUE; FEMALE; HAMILTON DEPRESSION RATING SCALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MARRIAGE; MIDDLE AGED; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; SHEEHAN DISABILITY SCALE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; WEIGHT CHANGE; CLINICAL TRIAL; COMPARATIVE STUDY; DEPRESSIVE DISORDER, MAJOR; DRUG POTENTIATION; KOREA; PSYCHOLOGICAL RATING SCALE; SINGLE BLIND PROCEDURE; TAIWAN;

ANTIDEPRESSIVE AGENTS; ARIPIPRAZOLE; DEPRESSIVE DISORDER, MAJOR; DRUG SYNERGISM; FEMALE; HUMANS; KOREA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SINGLE-BLIND METHOD; TAIWAN; TREATMENT OUTCOME;

EID: 84930542066     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2015.04.020     Document Type: Article

References (99)

1. Baldomero E.B., Ubago J.G., Cercos C.L., Ruiloba J.V., Calvo C.G., Lopez R.P. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress Anxiety 2005, 22:68-76.
2. Bauer M., Adli M., Ricken R., Severus E., Pilhatsch M. Role of lithium augmentation in the management of major depressive disorder. CNS Drugs 2014, 28:331-342.
3. Berman R.M., Fava M., Thase M.E., Trivedi M.H., Swanink R., McQuade R.D., et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009, 14:197-206.
4. Berman R.M., Marcus R.N., Swanink R., McQuade R.D., Carson W.H., Corey-Lisle P.K., et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. JClin Psychiatry 2007, 68:843-853.
5. Beyer-Westendorf J., Buller H. External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different?. JThromb Haemost 2011, 9:2153-2158.
6. Blier P., Gobbi G., Turcotte J.E., de Montigny C., Boucher N., Hebert C., et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 2009, 19:457-465.
7. Blier P., Ward H.E., Tremblay P., Laberge L., Hebert C., Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010, 167:281-288.
8. Bschor T., Baethge C. No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy. Acta Psychiatr Scand 2010, 121:174-179.
9. Carpenter L.L., Yasmin S., Price L.H. Adouble-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 2002, 51:183-188.
10. Carvalho A.F., Berk M., Hyphantis T.N., McIntyre R.S. The integrative management of treatment-resistant depression: a comprehensive review and perspectives. Psychother Psychosom 2014, 83:70-88.
11. Chen J., Gao K., Kemp D.E. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr Opin Psychiatry 2011, 24:10-17.
12. Chen S.J., Hsiao Y.L., Shen T.W., Chen S.T. The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial. JClin Psychopharmacol 2012, 32:56-60.
13. Cipriani A., Furukawa T.A., Salanti G., Geddes J.R., Higgins J.P., Churchill R., et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009, 373:746-758.
14. Citrome L. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. Int J Clin Pract 2012, 66:356-368.
15. Connolly K.R., Thase M.E. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 2011, 71:43-64.
16. Deuschle M., Krumm B., Bindeballe N., Colla M., Hamann B., Lederbogen F., et al. Open-label non-randomized versus double-blind randomized antidepressive treatment: what are the advantages of clinical decision over randomization?. Pharmacopsychiatry 2004, 37:299-302.
17. Edwards S.J., Hamilton V., Nherera L., Trevor N. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation. Health Technol Assess 2013, 17:1-190.
18. Faridhosseini F., Sadeghi R., Farid L., Pourgholami M. Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Hum Psychopharmacol 2014, 29:216-223.
19. Fava M., Mischoulon D., Iosifescu D., Witte J., Pencina M., Flynn M., et al. Adouble-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom 2012, 81:87-97.
20. Fava M., Rush A.J., Wisniewski S.R., Nierenberg A.A., Alpert J.E., McGrath P.J., et al. Acomparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006, 163:1161-1172.
21. Fredman S.J., Fava M., Kienke A.S., White C.N., Nierenberg A.A., Rosenbaum J.F. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. JClin Psychiatry 2000, 61:403-408.
22. Furberg C.D., Soliman E.Z. Double-blindness protects scientific validity. JThromb Haemost 2008, 6:230-231.
23. Garcia-Toro M., Medina E., Galan J.L., Gonzalez M.A., Maurino J. Treatment patterns in major depressive disorder after an inadequate response to first-line antidepressant treatment. BMC Psychiatry 2012, 12:143.
24. Gaynes B.N., Dusetzina S.B., Ellis A.R., Hansen R.A., Farley J.F., Miller W.C., et al. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D. JClin Psychopharmacol 2012, 32:114-119.
25. George T.P., Sacco K.A., Vessicchio J.C., Weinberger A.H., Shytle R.D. Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study. JClin Psychopharmacol 2008, 28:340-344.
26. Goss A.J., Kaser M., Costafreda S.G., Sahakian B.J., Fu C.H. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. JClin Psychiatry 2013, 74:1101-1107.
27. Han C., Pae C.U. Pain and depression: a neurobiological perspective of their relationship. Psychiatry Investig 2015, 12(1):1-8.
28. Han C., Wang S.M., Kato M., Lee S.J., Patkar A.A., Masand P.S., et al. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. Expert Rev Neurother 2013, 13:851-870.
29. Han C., Wang S.M., Seo H.J., Lee B.C., Jeon H.J., Kim W., et al. Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial- or non-responsive to current antidepressants: a multi-center, naturalistic study. JPsychiatr Res 2014, 49:75-82.
30. Han C., Yeh T.L., Kato M., Sato S., Chang C.M., Pae C.U. Management of chronic depressive patients with residual symptoms. CNS Drugs 2013, 27(Suppl.1):S53-S57.
31. Hirschfeld R.M., Montgomery S.A., Aguglia E., Amore M., Delgado P.L., Gastpar M., et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. JClin Psychiatry 2002, 63:826-837.
32. Huang K.L., Lu W.C., Wang Y.Y., Hu G.C., Lu C.H., Lee W.Y., et al. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials. Aust N Z J Psychiatry 2014, 48(7):663-671.
33. Ji L., Pan S., Marti-Jaun J., Hanseler E., Rentsch K., Hersberger M. Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese. Clin Chem 2002, 48:983-988.
34. Jing Y., Guo Z., Kalsekar I., Forbes R.A., Hebden T., Thase M.E. Dosing patterns of aripiprazole and quetiapine for adjunctive treatment of major depressive disorder (2006-2010). Int Clin Psychopharmacol 2013, 28:87-90.
35. Jon D.I., Kim do H., Seo H.J., Kwon Y.J., Kim M.D., Yang J.C., et al. Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: a 6-week prospective, open-label, multicenter study. Clin Neuropharmacol 2013, 36:157-161.
36. Kamijima K., Higuchi T., Ishigooka J., Ohmori T., Ozaki N., Kanba S., et al. Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study). JAffect Disord 2013, 151:899-905.
37. Kavale K. The efficacy of stimulant drug treatment for hyperactivity: a meta-analysis. JLearn Disabil 1982, 15:280-289.
38. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105.
39. Koesters M., Guaiana G., Cipriani A., Becker T., Barbui C. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br J Psychiatry 2013, 203:179-187.
40. Kohler S., Unger T., Hoffmann S., Steinacher B., Fydrich T., Bschor T. Comparing augmentation with non-antidepressants over sticking to antidepressants after treatment failure in depression: a naturalistic study. Pharmacopsychiatry 2013, 46:69-76.
41. Kornbluh R., Papakostas G.I., Petersen T., Neault N.B., Nierenberg A.A., Rosenbaum J.F., et al. Asurvey of prescribing preferences in the treatment of refractory depression: recent trends. Psychopharmacol Bull 2001, 35:150-156.
42. Lenox-Smith A.J., Jiang Q. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Int Clin Psychopharmacol 2008, 23:113-119.
43. Licht R.W., Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacol Berl 2002, 161:143-151.
44. Lin C.H., Lin S.H., Jang F.L. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study. JClin Psychopharmacol 2011, 31:563-568.
45. Lyoo I.K., Yoon S., Kim T.S., Hwang J., Kim J.E., Won W., et al. Arandomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder. Am J Psychiatry 2012, 169:937-945.
46. Marcus R.N., McQuade R.D., Carson W.H., Hennicken D., Fava M., Simon J.S., et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. JClin Psychopharmacol 2008, 28:156-165.
47. Mischoulon D., Nierenberg A.A., Kizilbash L., Rosenbaum J.F., Fava M. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can J Psychiatry 2000, 45:476-481.
48. Mischoulon D., Witte J., Levy M., Papakostas G.I., Pet L.R., Hsieh W.H., et al. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. JClin Psychiatry 2012, 73:353-357.
49. Mohr P., Czobor P. Subject selection for the placebo- and comparator-controlled trials of neuroleptics in schizophrenia. JClin Psychopharmacol 2000, 20:240-245.
50. Murray C.J., Lopez A.D. Evidence-based health policy-lessons from the global burden of disease Study. Science 1996, 274:740-743.
51. Murray C.J., Lopez A.D. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, & risk factors in 1990 projected to 2020 1996, Cambridge, MA.
52. Nehama Y., Rabinowitz I., Baruch Y., Mandel A., Lurie I., Barak Y. Debunking the placebo effect in depression: the effect of patient and investigator expectation on escitalopram efficacy. Int Clin Psychopharmacol 2014, 29:106-110.
53. Nelson J.C., Papakostas G.I. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009, 166:980-991.
54. Nelson J.C., Papakostas G.I. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of Placebo-controlled randomized trials. Am J Psychiatry 2009.
55. Nierenberg A.A., Trivedi M.H., Gaynes B.N., Mitchell J., Davis L.L., Husain M.M., et al. Effectiveness study of venlafaxine-XR Combined with aripiprazole for chronic or recurrent major depressive disorder. Aust N Z J Psychiatry 2009, 43:956-967.
56. Pae C.U. Evidence-based treatment for depressive disorder. Psychiatry Investig 2015, 12(2):278-279.
57. Pae C.U., Forbes A., Patkar A.A. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs 2011, 25:109-127.
58. Pae C.U., Han C., Jun T.Y. Do we need more than one antidepressant for patients with major depressive disorder?. Expert Rev Neurother 2011, 11:1561-1564.
59. Pae C.U., Jeon H.J., Lee B.C., Seo H.J., Kim S.G., Park E.J., et al. Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: a 12-week prospective open-label multicentre study. Int Clin Psychopharmacol 2013.
60. Pae C.U., Patkar A.A. Clinical issues in use of atypical antipsychotics for depressed patients. CNS Drugs 2013, 27(Suppl 1):39-45.
61. Pae C.U., Patkar A.A., Jun T.Y., Lee C., Masand P.S., Paik I.H. Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. Depress Anxiety 2006.
62. Pae C.U., Seo H.J., Lee B.C., Seok J.H., Jeon H.J., Paik J.W., et al. Ameta-analysis comparing open-label versus placebo-controlled clinical trials for aripiprazole augmentation in the treatment of major depressive disorder: lessons and promises. Psychiatry Investig 2014, 11:371-379.
63. Pae C.U., Wang S.M., Han C., Lee S.J., Patkar A.A., Masand P.S. Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting. Int Clin Psychopharmacol 2014, 29:116-119.
64. Pae C.U., Wang S.M., Han C., Lee S.J., Patkar A.A., Masand P.S. Quetiapine augmentation for depression: dosing pattern in routine practice. Int Clin Psychopharmacol 2015, 30:54-58.
65. Pae C.U., Wang S.M., Han C., Lee S.J., Patkar A.A., Masand P.S., et al. Vortioxetine: a meta-analysis of 12 short-term, randomised, placebo-controlled clinical trials for the treatment of major depressive disorder. JPsychiatry Neurosci 2015, 40(3):174-186.
66. Pajonk F.G., Holzbach R., Naber D. Comparing the efficacy of atypical antipsychotics in open uncontrolled versus double-blind controlled trials in schizophrenia. Psychopharmacol Berl 2002, 162:29-36.
67. Papakostas G.I. Major depressive disorder: psychosocial impairment and key considerations in functional improvement. Am J Manag Care 2009, 15:S316-S321.
68. Papakostas G.I. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. JClin Psychiatry 2009, 70(Suppl.6):16-25.
69. Papakostas G.I. The efficacy, tolerability, and safety of contemporary antidepressants. JClin Psychiatry 2010, 71(Suppl.E1):e03.
70. Papakostas G.I., Fava M. Ameta-analysis of clinical trials comparing milnacipran, a serotonin-norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. Eur Neuropsychopharmacol 2007, 17:32-36.
71. Papakostas G.I., Mischoulon D., Shyu I., Alpert J.E., Fava M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry 2010, 167:942-948.
72. Papakostas G.I., Petersen T.J., Kinrys G., Burns A.M., Worthington J.J., Alpert J.E., et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. JClin Psychiatry 2005, 66:1326-1330.
73. Papakostas G.I., Shelton R.C., Zajecka J.M., Etemad B., Rickels K., Clain A., et al. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry 2012, 169:1267-1274.
74. Papakostas G.I., Thase M.E., Fava M., Nelson J.C., Shelton R.C. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007, 62:1217-1227.
75. Patkar A.A., Pae C.U. Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder. CNS Drugs 2013, 27(Suppl.1):S29-S37.
76. Poirier M.F., Boyer P. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Br J Psychiatry 1999, 175:12-16.
77. Quitkin F.M., Rabkin J.G., Ross D., Stewart J.W. Identification of true drug response to antidepressants. Use of pattern analysis. Arch Gen Psychiatry 1984, 41:782-786.
78. Ruhe H.G., Huyser J., Swinkels J.A., Schene A.H. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. JClin Psychiatry 2006, 67:1836-1855.
79. Rush A.J. STAR*D: what have we learned?. Am J Psychiatry 2007, 164:201-204.
80. Rush A.J., Trivedi M.H., Stewart J.W., Nierenberg A.A., Fava M., Kurian B.T., et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011, 168:689-701.
81. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163:1905-1917.
82. Rush A.J., Trivedi M.H., Wisniewski S.R., Stewart J.W., Nierenberg A.A., Thase M.E., et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. NEngl J Med 2006, 354:1231-1242.
83. Simon J.S., Nemeroff C.B. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. JClin Psychiatry 2005, 66:1216-1220.
84. Souery D., Serretti A., Calati R., Oswald P., Massat I., Konstantinidis A., et al. Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study. World J Biol Psychiatry 2011, 12:364-375.
85. Spielmans G.I., Berman M.I., Linardatos E., Rosenlicht N.Z., Perry A., Tsai A.C. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 2013, 10:e1001403.
86. Su K.P., Wang S.M., Pae C.U. Omega-3 polyunsaturated fatty acids for major depressive disorder. Expert Opin Investig Drugs 2013.
87. Swift J.K., Callahan J.L. The impact of client treatment preferences on outcome: a meta-analysis. JClin Psychol 2009, 65:368-381.
88. Szegedi A., Jansen W.T., van Willigenburg A.P., van der Meulen E., Stassen H.H., Thase M.E. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. JClin Psychiatry 2009, 70:344-353.
89. Szegedi A., Muller M.J., Anghelescu I., Klawe C., Kohnen R., Benkert O. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. JClin Psychiatry 2003, 64:413-420.
90. Taylor D., Sparshatt A., Varma S., Olofinjana O. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ 2014, 348:g1888.
91. TenHave T.R., Coyne J., Salzer M., Katz I. Research to improve the quality of care for depression: alternatives to the simple randomized clinical trial. Gen Hosp Psychiatry 2003, 25:115-123.
92. Thase M.E. Antidepressant combinations: widely used, but far from empirically validated. Can J Psychiatry 2011, 56:317-323.
93. Thase M.E. Treatment-resistant depression: prevalence, risk factors, and treatment strategies. JClin Psychiatry 2011, 72:e18.
94. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163:28-40.
95. Uher R., Mors O., Rietschel M., Rajewska-Rager A., Petrovic A., Zobel A., et al. Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. JClin Psychiatry 2011, 72:1478-1484.
96. Wang S.M., Han C., Lee S.J., Patkar A.A., Masand P.S., Pae C.U. Vilazodone for the treatment of major depressive disorder: focusing on its clinical studies and mechanism of action. Psychiatry Investig 2015, 12(2):155-163.
97. Warden D., Rush A.J., Trivedi M.H., Fava M., Wisniewski S.R. The STAR*D project results: a comprehensive review of findings. Curr Psychiatry Rep 2007, 9:449-459.
98. Yoshimura R., Kishi T., Hori H., Ikenouchi-Sugita A., Katsuki A., Umene-Nakano W., et al. Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2012.
99. Zimmerman M., Posternak M.A., Chelminski I. Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. JPsychiatr Res 2004, 38:577-582.